What Are the Risk Factors for Epilepsy Among Patients With Craniosynostosis?

Dani Stanbouly1, Blaine Radley2, Barry Steinberg3

  • 1Dental Student, Columbia University College of Dental Medicine, New York, NY.

Insights

This study identified key risk factors for epilepsy in craniosynostosis patients. Hydrocephalus, obstructive sleep apnea (OSA), and brain compression (BC) significantly increase epilepsy risk.

Area of Science:

  • Neurology
  • Pediatric Neurosurgery
  • Medical Genetics

Background:

  • Craniosynostosis, a condition of premature skull fusion, is associated with various neurological complications.
  • Epilepsy is a significant concern in children with craniosynostosis, impacting long-term outcomes.
  • Identifying specific risk factors is crucial for timely intervention and management.

Purpose of the Study:

  • To determine the independent risk factors associated with the development of epilepsy in patients diagnosed with craniosynostosis.
  • To analyze the influence of specific comorbidities and demographic factors on epilepsy occurrence.

Main Methods:

  • Retrospective cohort study utilizing the Kids' Inpatient Database (2000-2012).
  • Included patients diagnosed with craniosynostosis.
  • Logistic regression analysis was performed to identify predictor variables for epilepsy, including obstructive sleep apnea (OSA), hydrocephalus, and brain compression (BC).

Main Results:

  • A total of 4,709 patients with craniosynostosis were analyzed; 5.2% (244) had epilepsy.
  • Hydrocephalus (OR, 6.6), OSA (OR, 3.0), and brain compression (BC) (OR, 2.4) were identified as independent risk factors for epilepsy.
  • Black patients and those residing in smaller metropolitan areas (50,000-249,999 population) showed increased epilepsy risk.

Conclusions:

  • Hydrocephalus, OSA, and BC are significant risk factors for epilepsy in craniosynostosis patients.
  • Demographic factors, including race and geographic location, are also associated with increased epilepsy risk.
  • These findings highlight the need for targeted surveillance and management strategies for epilepsy in this patient population.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
316
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
633
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
698
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
485
Cranial and Spinal Meninges01:19

Cranial and Spinal Meninges

The cranial and spinal meninges are complex protective structures surrounding the central nervous system (CNS), consisting of the brain and spinal cord. These meninges consist of the dura mater, the arachnoid mater, and the pia mater. They protect the CNS, provide structural support, and aid in circulating cerebrospinal fluid (CSF).
Cranial Meninges
These meningeal layers cover the cranium. The dura mater is the outermost layer of cranial meninges. It is a thick and durable membrane of dense...
1.8K